Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

NCT05894499 · clinicaltrials.gov ↗
COMPLETED
Status
13309
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

ModernaTX, Inc.